CA-KRAKEN
11.2.2021 15:32:09 CET | Business Wire | Press release
Kraken Digital Asset Exchange, one of the world’s largest cryptocurrency exchanges, today announced its backing of the newly launched Kraken Ventures, an independent investment fund targeting early stage companies and protocols across the crypto and fintech ecosystem. The fund will invest in the technologies powering the next wave of crypto and fintech innovation and provide entrepreneurs with the financial resources and industry expertise needed to build and scale their business.
Kraken Ventures will focus on areas including fintech, crypto companies & protocols, decentralized finance (DeFi) as well as enabling technologies such as AI, Machine and Deep Learning, Reg Tech, and cybersecurity. Kraken Ventures offers the best of both worlds in being a completely autonomous fund that’s backed by the resources and expertise of Kraken.
Led by a team with extensive experience in the crypto and financial services industry and leveraging its strategic partnership with Kraken, portfolio companies get access to the ideal environment for their teams to collaborate across the Kraken and broader fintech ecosystem. The fintech and crypto ecosystems will continue to be drawn closer together and Kraken Ventures will be investing at the intersection of these two dynamic industries.
Jesse Powell, co-founder and CEO of Kraken said: “As we enter the crypto industry’s next growth phase, Kraken Ventures will support entrepreneurs in making the financial system more open, inclusive, and transparent. With a strong team in place, Kraken Ventures offers the right combination of resources to bring the best ideas to their full potential. We’ve arrived at the point where crypto is starting to show its true potential, transforming the financial services industry and creating truly global, digital economies.”
Kraken Ventures will be led by Brandon Gath, who has 20 years of experience in the financial services and crypto industries. He most recently served as the Head of Corporate Development at Kraken and prior to joining Kraken helped lead CME Ventures, where he was an early investor in numerous unicorn startups across fintech, AI, Deep Learning, Quantum Computing and Crypto. He led early investments in Orbital Insight, Crosslend, Digital Currency Group, Nervana Systems, Crypto Facilities, Privitar, and Fortscale. Brandon has a wealth of professional experience ranging across venture capital, M&A, investing banking, and consulting. He holds an MBA from the University of Chicago in Entrepreneurial Finance.
Brandon Gath, General Partner of Kraken Ventures said: “Fintech and specifically crypto technology provides the opportunity to drastically change how businesses and consumers exchange and store value, invest, lend, borrow, and conduct global commerce. We take a long-term view on investing to add value from inception through each growth phase of our portfolio companies’ evolution. We will take a hands-on approach with our portfolio companies to provide guidance, new commercial opportunities and additional capital support. The possibility to leverage Kraken’s experience building a truly global, scalable platform enables us to support our portfolio companies from inception to market leadership. We’ve already identified some of the best opportunities out there and expect to announce our first investments in the near future.”
Brandon will be joined by Kirill Gourov and Akshi Federici . Kirill currently supports strategic investment for Kraken and previously managed blockchain investments for a New York-based multifamily office. Prior to this, he led blockchain strategy efforts at Expand Research, a subsidiary of The Boston Consulting Group. He has been actively involved in the Bitcoin community since early 2013 and has over 7 years of experience in the blockchain industry including investment, strategy development for both public and private chain applications, and business development for blockchain projects. Akshi Federici is a seasoned strategic operator with over 15 years of experience in the financial services and cryptocurrencies industries with The Boston Consulting Group, BlackRock, Conde Nast, ConsenSys, and Kraken.
For more information, please visit www.krakenventures.com
About Kraken
Based in San Francisco, Kraken is the world’s largest global digital asset exchange based on euro volume and liquidity. Kraken’s clients trade more than 50 digital assets and 7 different fiat currencies, including EUR, USD, CAD, GBP, JPY, CHF and AUD. Kraken was founded in 2011 and is the first digital asset exchange to have its market data displayed on the Bloomberg Terminal and one of the first to offer spot trading with margin, regulated derivatives and index services. Kraken is trusted by more than 5 million traders, institutions and authorities around the world.
Kraken is backed by investors including Hummingbird Ventures, Blockchain Capital and Digital Currency Group, among others. For more information about Kraken, please visit www.kraken.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005504/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom